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Abstract  
Background. Detailed information on the profile of Brugada syndrome (BrS) patients 
presenting their first arrhythmic event (AE) after prophylactic implantation of a 
cardioverter defibrillator (ICD) is limited.  
 Objectives. 1) To compare clinical, electrocardiographic, electrophysiologic and 
genetic profiles of patients who exhibited their first documented AE as aborted 
cardiac arrest (CA) (group A) with those in whom the AE was documented after 
prophylactic ICD implantation (group B); 2) To characterize group B patients’ profile   
using the Class II indications for ICD implantation established by 
HRS/EHRA/APHRS Expert Consensus Statement in 2013.   
Methods. A survey of 23 centers from 10 Western and 4 Asian countries enabled data 
collection of 678 BrS patients with AE (group A, n=426; group B, n=252). 
Results. First AE occurred in group B patients 6.7 years later than in group A (46.1+ 
13.3 vs. 39.4+15.1, P<0.001). Group B patients had a higher incidence of family 
history of sudden cardiac death (SCD) and SCN5A mutations. Of the 252 group B 
patients, 189 (75%) complied with the HRS/EHRA/APHRS indications whereas the 
remaining 63 (25%) did not. 
Conclusion. BrS patients with first AE documented after prophylactic ICD 
implantation exhibited their AE at a later age with a higher incidence of positive 
family history of SCD and SCN5A mutations compared to those presenting with an 
aborted CA. Only 75% of patients who suffered an AE after receiving a prophylactic 
ICD complied with the 2013 Class II indications, suggesting efforts are still required 
for improving risk stratification.                                                                                                                        
Keywords: ICD, arrhythmic risk stratification, sudden cardiac death, genetics, 
electrophysiologic study.
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                                                        INTRODUCTION 
Brugada syndrome (BrS) is an inherited arrhythmic disorder that may result in sudden 
cardiac death (SCD).1 Despite the considerable amount of publications on the topic 
since the first description of the syndrome2, the number of patients with documented 
ventricular arrhythmic events (AE) reported is relatively limited.  
Most prior studies have focused on patients with an aborted cardiac arrest (CA) as the 
presenting AE. The 2 largest European series gathered 623 and 254 patients presenting 
with an aborted CA while the largest Asian series from Japan5, South Korea6 and 
Thailand7 included 84, 77 and 65 patients respectively.  Based on these data a profile 
of BrS patients presenting with aborted CA has been drawn: male patients (>90%) in 
their fourth decade of life, most of them with spontaneous type 1-Brugada ECG who 
exhibited their AE without any warning symptoms. 
In contrast, detailed information regarding the profile of patients who exhibited their 
AE after prophylactic implantation of a cardioverter-defibrillator (ICD) is scarce and 
confined to 3 small series8-10 comprising up to 14 patients.9 Gaining insight into the 
profile of the patients who received and appropriately utilized a prophylactic ICD is 
important for determining whether ICD indications for these patients complied with 
those established by the HRS/EHRA/APHRS 2013 Expert Consensus Statement.11.   
We have recently organized a multicenter international survey on AE in BrS (the 
Survey on Arrhythmic events in BRUgada Syndrome, SABRUS)12 which collected 
data on a large cohort of 678 patients with AE’s from multiple Western and Asian 
countries. The present study has 2 main objectives: 
1. Compare the characteristics of patients with BrS who underwent a secondary 
prevention ICD implant with those who underwent a primary prevention device 
implant.  
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2. Analyze the profile of patients who exhibited their first AE after prophylactic ICD 
implantation based on the previously defined Class II indications for ICD 
implantation.11   
 
                                                                  METHODS 
Data source and center selection.  
A systematic Medline search was conducted in order to locate the largest academic EP 
centers having experience in the diagnosis and management of AE’s in the setting of BrS. 
Meta-analyses and case reports were excluded. The centers were requested to state whether 
their data originated from a single or from multiple institutions and to provide a list of 
participating institutions in order to prevent any duplication in data collection. 
Center recruitment.  
Out of 27 centers contacted, 23 (85%) agreed to participate. Sixteen centers (69.5%) 
reported their sole experience and 7 (30.5%) collected the experience of multiple 
institutions. A total of 678 patients were recruited from 10 Western (415 patients; 
61%) and 4 Asian (263 patients; 39%) countries (Supplemental Table 1).  
The study was approved by the Institutional Committee on Human Research at the 
Tel Aviv Sourasky Medical Center. 
Data acquisition. 
Study inclusion criteria consisted of 1) a typical Brugada type 1 ECG either 
spontaneously or following the intravenous administration of a sodium blocker drug; 
2) a first documented AE.  
Anonymous patient information was collected using a predefined questionnaire 
regarding the following: 1) mode of AE documentation (Group A or Group B, see 
below); 2) age at the time of the first AE; 3) gender; 4) proband status; 5) ethnicity 
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(Caucasian, Asian, other or unknown);  6) family history of SCD;  7) prior history of 
syncope ; 8) presence of spontaneous or drug-induced Brugada-ECG type 1; 9) 
inducibility of ventricular fibrillation (VF) at electrophysiologic study (EPS) and 10) 
results of genetic testing.  
In patients who had an AE documented after receiving a prophylactic ICD but did not 
comply with the  2013 guidelines indications11, the presence of QRS fragmentation 
(QRS-f) in leads V1-V3 (13), which was previously reported as a good predictor for 
AE8,13 was also collected. 
Definitions. 
Patient groups according to mode of AE documentation:  
- Group A: Patients with documented aborted CA in whom the diagnosis of BrS 
was made a posteriori.  
- Group B: Patients with an a priori diagnosis of BrS in whom prophylactic 
ICD implantation was performed and an AE triggering appropriate ICD shock 
therapy was documented during follow-up. 
Arrhythmic events: AE was defined as any sustained ventricular tachyarrhythmia 
documented during initial aborted CA (group A) or triggering ICD shock therapy 
(group B).  
HRS/EHRA/APHRS Expert Consensus Statement11: Current guidelines recommend 
prophylactic ICD implantation in patients with either spontaneous type 1 Brugada-ECG 
presenting with syncope judged likely to be caused by ventricular arrhythmia (Class IIa 
indication) or spontaneous or drug-induced type 1 ECG with inducible VF by programmed 
ventricular stimulation (Class IIb indication).   
Genetic analysis: When a SCN5A mutation was identified it was classified by its known 
pathogenicity.                   
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Statistical analysis.                                                                               
Assumptions of normality of the age distributions amongst patient subgroups were assessed 
by Kolmogorov–Smirnov test and Q-Q plots. Differences between group age means were 
assessed using a Welch t-test for two groups or a one-way ANOVA test for three groups. 
Differences in proportions were assessed by a Chi-square test or a Fisher's exact test as 
appropriate. Significance of linear trends for ordinal variables was calculated using a 
Mantel-Haenszel test. To assess factors influencing dichotomous variables in a multivariate 
fashion a binary logistic model method was utilized using influencing variables as 
independent variables.  Statistical significance was defined as P<0.05. All calculations 
were performed using SPSS vs. 24 (IBM, Armonk, NY, USA).   
 
RESULTS 
The clinical, ECG, EP and genetic findings of the 678 SABRUS patients in respect to 
mode of AE presentation (groups A and B) are presented in Table 1.  
Comparison between group A and group B.     
Demographics. The male/female ratio was similar in group A (10.5) and group B 
(10.8). Group B patients were 6.7 years older than group A patients at time of first AE 
(46.1+13.3 vs. 39.4+15.1 years, P<0.001). Since the survey recruited more patients 
from Western than Asian countries, there were more Caucasians in both groups but 
the proportion of Asians with AE was greater in group A (45% vs. 31% in group B, 
P<0.001).  
Proband status. The great majority (80%) of SABRUS patients were probands with a 
greater proportion in group A (84%) than in group B (74%) (P<0.001)  
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Clinical data. A family history of SCD was more frequently noted in group B (29%) 
compared with group A (17%) (P<0.001), as was a history of syncope (63% vs. 25%, 
P<0.001).                                    
ECG data. Spontaneous type 1 Brugada-ECG was observed in similar proportions of 
groups A and B patients (65% and 69%, respectively) (P=0.214).  
EP data. Group B patients underwent more EPS than group A (79% vs. 47%, 
P<0.001) and had a greater proportion of positive results (72% in group B vs 55% in 
group A, P<0.001).                                                                                                                                    
Genetic data. A greater proportion of patients in group A underwent genetic testing 
(74% and 67% for groups A and B, respectively, P=0.03). An SCN5A mutation was 
more frequently observed in group B (36%) than in group A (26%) (P=0.016); 
however, the difference did not reach statistical significance when comparing only 
proband patients (32.8% vs. 24.3%, P=0.070). 
Among patients with a family history of SCD, the proportion of patients with an 
SCN5A mutation was slightly higher in group B (42.1% vs. 35.8% in group A) but the 
difference was not statistically significant (P=0.474).  
Most of the SCN5A mutations were identified as pathogenic (56.34%) and likely 
pathogenic (23.24%) while 10.9% were classified as a “variant of unknown 
significance”, 0.8% as “benign” and for 9.9% the classification was unknown 
(Supplemental Figure 1). All SCN5A mutations are listed in Supplemental Table 2.  
Detailed characteristics of group B patients. 
Group B patients were divided into 3 subgroups based on the 2013 consensus 
statement on class II indications for ICD11: a) Group B1 (Class IIa indication): 112 
(44%) patients; b) Group B2 (Class IIb indication): 77 (31%) patients; c) Group B3 
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(neither Class IIa nor Class IIb indications): 63 (25%) patients. The clinical, ECG, EP 
and genetic findings in these subgroups are presented and compared in Table 2.  
Although the proportion of females in group B3 (13%) was greater than in group B1 
(9%) and group B2 (6%), this difference was not statistically significant. Group B3 
included a smaller proportion of patients aged 16-70 than the other 2 groups. A family 
history of SCD was more frequently noted in group B2 (39%) and group B3 (30%) as 
compared to group B1 (22%) (P=0.01). No significant differences were observed 
between the 3 subgroups with regard to age at first AE, ethnic origin and the presence 
of SCN5A mutation. However, when comparing between B3 patients vs. the 
remainder of the group B patients (B1+B2), there was a trend for more SCN5A 
mutation carriers in Group B3 (48% vs. 32%, P=0.067) (Supplemental Table 3). 
As expected by group definition criteria, prior syncope and spontaneous type 1 
Brugada-ECG predominated in group B1. Similarly, VF inducibility predominated in 
group B2 and was absent in group B3. 
Characteristics of group B3.  
The clinical, ECG, EP and genetic findings in the 63 group B3 patients are presented 
in Table 3. In 33 (52%) patients (group B3a) EPS was performed but yielded negative 
results while in the remaining 30 (48%) patients (group B3b) EPS was not performed. 
Table 4 provides detailed patient characteristics of these 2 subgroups. 
The only striking difference between these 2 subgroups of patients was the higher 
proportion of females in the non-inducible group (18% vs. 7%) but this difference did 
not reach statistical significance (P=0.261). QRS-f was found in ~ 30% of patients of 
either subgroup (30.3% and 30%, respectively) regardless of the presence of 
spontaneous type 1 Brugada-ECG.  
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When dividing group B into 3 equal subgroups according to the date of ICD 
implantation (from 9/1987 to 6/2016) there was a rise over the years of the proportion 
of patients who received an ICD without complying with conventional guidelines 
(Figure 1) (P=0.021 for trend). There was no difference in clinical characteristics of 
B3 patients (age, gender, ethnicity, familial history of SCD, prior syncope, ECG type) 
between the 3 periods.  
Using a logistic regression multivariate model, no single parameter identified group 
B3 patients (besides the definition of not having a conventional class II indication) 
(Supplemental Table 4).                                                                
                                                                    
                                                         DISCUSSION 
The strength of SABRUS comes from its large cohort of BrS patients who suffered 
their first documented AE either at the time of aborted CA or after a prophylactic ICD 
implantation. 
Comparison between group A and group B. 
The profile of group A patients from SABRUS was similar to previously reported in 
largest studies of CA survivors.3,4,5-7 However, besides the similarity in the male 
predominance (>90%) and the presence of spontaneous type 1 Brugada-ECG in about 
two thirds of patients in both groups, there were marked differences between the 2 
groups with regards to the other clinical, EP and genetic characteristics. 
Age at onset of AE.  Priori et al. noted that BrS-patients with a first AE documented after 
prophylactic ICD implantation8 were 14 years older than those presenting with aborted CA. 
14 In SABRUS the initial AE occurred 6.7 years later in group B. There are 2 possible 
explanations for this late occurrence of AE in group B patients:  a) the arrhythmias in group 
A patients could have a more malignant character striking the patient at a younger age; b) 
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the lack of effective ECG screening and arrhythmic risk assessment in the younger patient 
group contrasting with a better stratification in the older group.  
Ethnicity. In SABRUS a greater proportion of Asian patients were observed in group A.  
This difference in the mode of AE presentation between Caucasians and Asians could 
suggest a more malignant presentation of AE in Asians and/or a less effective screening 
recognition in Asian countries.  
Family history of SCD.  A higher incidence of family history of SCD was found in group B 
(29%) compared with group A patients (17%). It is noteworthy that in 3 large series of BrS 
patients3,4,8 and in the prospective study of Sarkozy et al15, the incidence of family history 
of SCD was highest in asymptomatic patients (30-58.7%), lowest in CA survivors (10-
40%), and intermediate (20-51%) in patients presenting with syncope. The reason for the 
concordant findings of a higher incidence of a family history of SCD in patients who did 
not present with aborted CA has not been previously addressed. One possible explanation 
could be that a substantial number of these patients were identified after routine familial 
screening following the SCD of a family member that notably increased their family 
history of SCD rate as compared to patients with aborted CA. 
Prior history of syncope. Priori and coworkers previously reported that a history of 
syncope was more frequently noted in patients with AE documented after 
prophylactic ICD implantation (50%)3 than in CA survivors (23.5%).4 Similar results 
were found in SABRUS with figures of 63% and 25%, respectively.  Such difference 
is likely due to the fact that a previous syncope was one of the inclusion criteria in the 
B1 subgroup fulfilling Class IIa indication.    
Arrhythmia inducibility. The results of SABRUS also showed a higher proportion of 
patients with inducible VF in group B (72% vs. 55% in group A). Such results are 
consistent with the fact that arrhythmia inducibility was the inclusion criterion in the 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
 
14 
B2 subgroup fulfilling Class IIb indication. In addition, it is possible that the 
stimulation protocols used in group B patients were more aggressive (in order to 
minimize false negative results) than in group A (where EPS was mainly performed 
for academic purpose since the EP results were unlikely to affect patient management 
with ICD).    
Genetic findings. The latest meta-analysis by Wu et al.16 indicated that an SCN5A gene 
mutation did not increase the risk for future cardiac events. In contrast, a recent Japanese 
study showed that an SCN5A mutation was a significant predictor of cardiac events in BrS 
probands.17 In SABRUS, an SCN5A mutation was more frequently observed in group B 
(36%) than in group A (26%) (P=0.007). 
The fact that a greater proportion of group B patients had a family history of SCD (29% vs. 
17% in group A, P<0.001) and that a greater (albeit non-significant) incidence of SCN5A 
mutation was found among those patients with a family history of SCD in group B could 
explain our findings.  
Profile of group B patients. 
In addition to groups B1 and B2 who fulfilled Class II indications, the survey showed 
for the first time another sizeable group (B3) comprising 25% of group B patients, 
who did not fulfill these indications. Besides a higher incidence of a family history of 
SCD in group B2 and group B3 as compared to group B1 as well as intergroup 
differences due to group criteria definitions, there were no significant differences 
between these 3 groups in regard to patients’ age at time of AE, ethnic origin, and the 
presence of SCN5A mutation.  
The fact that group B1 comprised more patients than group B2 is consistent with the 
results of the Multicenter Japanese study on the long-term prognosis of BrS patients 
with no previous CA, based on Class II indications for ICD implantation.18 Such 
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results validate the classification adopted in the Expert Consensus Statement11 
establishing that patients with Class IIa indication exhibit an increased risk as 
compared to those with Class IIb indication.  
Characteristics of group B3 patients. 
This group comprised 2 subgroups of similar size: one in whom EPS did not induce 
arrhythmias (n=33) and the second in whom EPS was not performed (n=30).  
Interestingly the proportion of Caucasians and Asians in group B3 among group B 
patients was similar (25% and 24.3%, respectively). 
Priori et al.8 and Sieira et al.9 previously reported small cohorts of patients without 
Class IIa or IIb ICD indications who exhibited an AE during follow-up after 
prophylactic ICD implantation. 
Taking into account that arrhythmia inducibility is a critical factor for deciding upon 
prophylactic ICD implantation in BrS, aggressiveness of the protocol of programmed 
ventricular stimulation (PVS) used is of paramount importance.19,20 In addition, in 
SABRUS the non-inducible subgroup (B3a) included a relative high proportion of 
females who have been shown to exhibit a lower inducibility rate of VF than males.21  
Although it is tempting to speculate that aggressive PVS protocols19,20 could have 
resulted in a higher inducibility rate of arrhythmias and enabled inclusion of the 
inducible patients in the B2 group, one should recognize that doing so might increase 
the number of false positive responses and unnecessary ICD implants.  
The issue of patients in whom EPS was not performed and who received a 
prophylactic ICD not based on Class II indications (subgroup B3b), just to exhibit an 
AE during follow-up has not been previously addressed.  Our data showed that the 
proportion of such patients has been growing over the years, probably due to the 
increasing doubts of the EP community concerning the role of EPS in predicting 
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arrhythmic risk in BrS. It is likely that performance of EPS in subgroup B3b would 
have yielded positive results in some of them, thus enabling their inclusion in group 
B2. 
Careful analysis of the B3 group characteristics failed to identify any obvious clinical 
or laboratory criteria used as single factor that could raise suspicion of the very high 
arrhythmic risk of these patients.  
It is noteworthy that the total number of patients treated with a prophylactic ICD 
without appropriate shocks based on non-conventional indications such as in group 
B3 was unknown from our survey results.  
Study limitations.  
The survey is not a multicenter prospective study but rather a retrospective cumulative 
analysis of results from the largest EP centers which have experience with BrS.  The 
definitions of family history of SCD and syncope, as well as the PVS protocol were 
left at the discretion of the participant centers. There was no information about the 
patients’ or physicians’ involvement in the decision to implant a prophylactic ICD in 
those patients who did not fulfill Class II indications.  
Clinical implications. 
The results of SABRUS confirm the validity of Class II indications established by the 
Expert Committee11 in 75% of the SABRUS patients without previous CA.  However, 
the fact that the remaining 25% of patients exhibited AE despite the fact they did not 
fulfill the conditions justifying this implantation based on these guidelines, is of a 
great concern. A strict application of the guidelines recommendations in these patients 
would have discarded ICD implantation and could have had a fatal outcome. On the 
other hand widening the indications for prophylactic ICD implantation in BrS based 
on the data provided by SABRUS in group B3 is likely to result in unnecessary ICD 
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implantations in a considerable amount of patients. Thus, our data suggest that major 
efforts should be made to assign these patients to group B1 or B2. However, one 
should admit that despite these efforts it might be that the patient’s clinical and 
familial history as well as the patient’s and the family’s wishes will lead to ICD 
implantation despite the lack of strict adherence to Class II indications. We believe 
that this possibility should be kept to the minimum. Although there might well be a 
larger pressure for patients, families and doctors to implant a prophylactic ICD in the 
case of familial SCD, this is not currently supported by guidelines because of the high 
chances of unnecessary exposure to invasive ICD therapy and its associated risks. 
Taking into account the limitations and inconsistencies with taking a family history of 
SCD in the current retrospective study, there is certainly a need for more robust 
family history data in BrS patients.  
Conclusions. 
For the first time SABRUS describes the profile of patients with BrS who developed 
an AE after prophylactic ICD implantation in a large patient population. The profile 
of these patients differs from that of CA survivors including a non-negligible 
proportion of patients who did not comply with the conventional guidelines. Major 
efforts are still necessary for improving arrhythmic risk stratification in BrS. 
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                                                              Legends  
Figure 1. Evolution over the years of the indication of prophylactic ICD implantation 
in Group B patients who exhibited arrhythmic events (n=252). Patients who exhibited 
arrhythmic events after prophylactic ICD implantation were divided into 3 equal 
subgroups according to the date of ICD implantation. A rise is noted over the years of 
the proportion of patients who received an ICD without complying with conventional 
guidelines indication (Group B3).         
Definitions of groups B1, B2 and B3 are given in the text.  
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Table 1: Comparison between group A and group B 
 
Group A Group B P value
(n=426) (n=252)
Gender
Male 390 (92) 229 (91)
Female 36 (8) 23 (9)
Age at AE
All patients (years) 39.4±15.1 46.1±13.3 <0.001
Age distribution < 16 25 (6) 4 (2)
16-70 395 (93) 245 (97)
>70 6 (1) 3 (1)
Ethnicity
Caucasian 204 (48) 160 (63)
Asian 192 (45) 78 (31)
Other 30 (7) 14 (6)
Proband status
Positive   356 (84) 186 (74)
Negative  40 (9) 48 (19)
Unknown 30 (7) 18 (7) 0.961
Family history of SCD
Yes 73 (17) 72 (29)
No 315 (74) 153 (61)
Unknown 38 (9) 27 (11) 0.443
Prior history of syncope
Yes 106 (25) 159 (63)
No 320 (75) 93 (37)
Spontaneous type 1 ECG
Yes 276 (65) 175 (69)
No 150 (35) 77 (31)
VF inducibility during EPS
EPS performed 200 (47) 200 (79) <0.001
Positive EPS 109 (55) 144 (72)
Negative EPS 91 (46) 56 (28)
Presence of SCN5A  mutation
Genetics performed 317 (74) 168 (67) <0.05
SCN5A  positive 82 (26) 61 (36)
SCN5A  negative 235 (74) 107 (64)
<0.001
<0.05
0.763
<0.001 
<0.05
<0.001
<0.001
<0.001
0.214
 
All numbers are presented as number of patients (percent of patients in specific group).   
AE: arrhythmic event; EPS: electrophysiological study; SCD: sudden cardiac death;  
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Table 2. Detailed characteristics of group B 
 
B1 B2 B3
Class II a Class II b No Class IIa or IIb P-value
Syncope + Type 1 ECG Inducible VF
No of patients 112 (44.4) 77 (30.6) 63 (25)
Gender
Male 102 (91) 72 (94) 55 (87)
Female 10 (9) 5 (6) 8 (13)
M/F ratio 10.2 14.4 6.8
Age at AE
All patients (years) 44.7±12.7 48.0±12.5 46.5±15 0.237
Age distribution < 16 1 (1) 0 (0) 3 (5)
16-70 111 (99) 75 (97) 59 (94)
>70 0 (0) 2 (3) 1 (2)
Ethnicity
Caucasian 66 (59) 54 (70) 40 (63)
Asian 42 (38) 17 (22) 19 (30)
Others 4 (4) 6 (8) 4 (6)
Proband status
Positive 91 (81) 56 (73) 39 (62)
Negative 17 (15) 16 (21) 15 (24)
Unknown 4 (4) 5 (6) 9 (14) <0.05*#
Family history of SCD
Yes 23 (22) 30 (39) 19 (30)
No 81 (78) 40 (52) 32 (51)
Unknown 8 (7) 7 (9) 12 (19) 0.043#
Prior history of syncope
Yes 112 (100) 20 (26) 27 (43)
No 0 (0) 57 (74) 36 (57)
Spontaneous type 1 ECG
Yes 112 (100) 37 (48.1) 26 (41)
No 0 (0) 40 (51.9) 37 (59)
VF inducibility during EPS
EPS performed 90 (80) 77 (100) 33 (52) <0.001&#
Positive EPS 67 (74) 77 (100) 0 (0)
Negative EPS 23 (26) 0 (0) 33 (100)
Presence of SCN5A  mutation
Genetics performed 71 (63) 53 (69) 44 (70) 0.61
SCN5A  positive 25 (35) 15 (28) 21 (48)
SCN5A  negative 46 (65) 38 (72) 23 (52)
<0.001*&#
<0.001*&#
0.184
<0.001&#
0.136
0.445
0.042#
0.113
0.010*&
 
All numbers are presented as number of patients (percent of patients in specific group).                      
Abbreviations as in Table 1.  
* Group B1 significantly different from the others, & Group B2 significantly different from 
the others, # Group B3 significantly different from the others. 
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Table 3. Comparison between B3 subgroups 
 
B3a B3b
No Class IIa or IIb No Class IIa or IIb
Non inducible VF EPS not performed 
No of patients 33 (52.4) 30 (47.6)
Gender
Male 27 (82) 28 (93)
Female 6 (18) 2 (7)
Age at AE
All patients (years) 47.6±16.2 45.2±13.7 0.529
Age distribution < 16 2 (6) 1 (3)
16-70 30 (91) 29 (97)
>70 1 (3) 0 (0)
Ethnicity
Caucasian 24 (73) 16 (53)
Asian 8 (24) 11 (37)
Others 1 (3) 3 (10)
Proband status
Positive  22 (67) 17 (57)
Negative  8 (24) 7 (23)
Unknown 3 (9) 6 (20) 0.289
Family history of SCD
Yes 11 (33) 8 (27)
No 18 (55) 14 (47)
Unknown 4 (12) 8 (27) 0.142
Prior history of syncope
Yes 15 (45) 12 (40)
No 18 (55) 18 (60)
Spontaneous type 1 ECG
Yes 14 (42) 12 (40)
No 19 (58) 18 (60)
VF inducibility during EPS
EPS performed 33 (100) 0 (0) <0.001
Positive EPS 0 (0) 0 (0)
Negative EPS 33 (100) 0 (0)
Presence of SCN5A  mutation
Genetics performed 24 (73) 20 (67) 0.601
SCN5A  positive 11 (46) 10 (50)
SCN5A  negative 13 (54) 10 (50)
0.839
P value
N/A
0.783
0.261
1.00
0.197
0.909
0.662
0.845
 
All numbers are presented as number of patients (percent of patients in specific group).                       
Abbreviations as in Table 1.  
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Table 4. ICD indications in subgroup B3 (group B patients without a class IIa or IIb 
indication)  
 
          EPS 
           Symptoms         Asymptomatic          Syncope        Asymptomatic              Syncope
         ECG 
  4 (22.2)
      13/1          12/0
Fragmented  QRS  Yes
No 
N.A
Family history SCD Yes
No
N.A
SCN5A
 positive
6 1 - 10Proband Positive 10 1 - 11
Group B3a  (n=33) Group B3b  (n=30)
Non-inducible Not performed
         18 (54.5)        15 (45.5)          18 (60)          12 (40)
  ST1 -    ST1 -    ST1 +    ST1 -
0 (0) 0 (0)
M/F   4/0 - 10/2   4/2 -
    12 (66.7)    6 (33.3)
12/0
5 1 - 4 5 1 - 3
- 7
2 2 - 1 4 2 - 2
7 1 - 10 3 3
- 0
9 1 - 8 3 0 - 9
4 1 - 6 5 3
- 3
5 2 - 5 5 3 - 2
1 2 - 1 4 3
  12 (100)
      ST1 + 
    14 (77.8)
     ST1 +    ST1 -
  15 (100)
    ST1 + 
 
All numbers are presented as number of patients (percent of patients in specific group).                     
EPS: electrophysiological study; M: male; F: female; SCD: sudden cardiac death;              
ST1 +: spontaneous type 1 Brugada ECG; ST1 - : no spontaneous type 1 Brugada ECG.    
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